| n | % | ||
| No. of patients | 19 | ||
| Pt age (yr) | Median (Range) | 65 (51 - 79) | |
| No. ECOG performance status | 0 | 13 | 68.4 |
| 1 | 4 | 21.1 | |
| 2 | 2 | 10.5 | |
| Gleason score at diagnosis | ≤6 | 2 | 10.5 |
| 7 | 2 | 10.5 | |
| ≥8 | 14 | 73.7 | |
| unknown | 1 | 5.3 | |
| Baseline PSA before DEC (ng/mL) | Median (Range) | 67.0 (9.1 - 1102) | |
| Median time from diagnosis to ADT (m) | Median (Range) | 1.0 (0.0 - 1062) | |
| Median time from diagnosis to docetaxel (m) | Median (Range) | 27.0 (3.0 - 1313) | |
| Median time from DP to DEC (m) | Median (Range) | 13.0 (4.0 - 29.0) | |
| Median time from CRPC to DEC (m) | Median (Range) | 17.0 (5.0 - 57.0) | |
| Median cycles of docetacel before DEC | 6 (1 - 12) | ||
| Metastatic site | Bone | 18 | 94.7 |
| Lymph nodes | 13 | 68.4 | |
| Visceral | 5 | 26.3 | |
| Other | 1 | 5.3 | |
| Prior therapy | Surgery | 4 | 21.1 |
| Radiation | 2 | 10.5 | |
| Medical castration | 15 | 78.9 | |
| Surgical castration | 4 | 21.1 | |
| Bicalutamide | 19 | 100.0 | |
| Flutamide | 12 | 63.2 | |
| Chlormadinone acetate | 3 | 15.8 | |
| EMP | 16 | 84.2 | |
| Other | 2 | 10.5 |